PHVS Pharvaris N.V.
$38.02
Pharvaris N.V. (PHVS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
In line
Selling ran in line with PHVS's own trailing one-year pace, with 88% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
5 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
11
55 transactions
Purchases
$0
0 shares
Sales
$13.6M
419,979 shares
Net activity
-$13.6M
purchases less sales
How much of that selling was preplanned? 88% planned / 12% discretionary
10b5-1 plan sales
$11.9M
45 transactions · 364,464 shares
Discretionary sales
$1.7M
10 transactions · 55,515 shares
Largest single sale: $1.1M.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Glassman Robert | Director | Sell 10b5-1 | 8,000 | $37.55 | $300.4K | 10,500 −43.2% of holding | |
| Lu Peng | President | Sell 10b5-1 | 15,000 | $40.68 | $610.1K | 65,179 −18.7% of holding | |
| Modig Berndt | Chief Executive Officer | Sell 10b5-1 | 2,292 | $34.77 | $79.7K | 130,625 −1.7% of holding | |
| Modig Berndt | Chief Executive Officer | Sell 10b5-1 | 2,292 | $34.97 | $80.2K | 132,917 −1.7% of holding | |
| Lesage Anne 2 fills | Chief Early Development | Sell 10b5-1 | 58,575 | $35.48 | $2.1M | 93,969 −38.4% of holding | |
| Schikan Johannes Gerardus Christiaan Petrus | Director | Sell 10b5-1 | 30,712 | $35.49 | $1.1M | 315,167 −8.9% of holding | |
| Lesage Anne 3 fills | Chief Early Development | Sell 10b5-1 | 17,597 | $35.06 | $616.9K | 124,672 −12.4% of holding | |
| Schikan Johannes Gerardus Christiaan Petrus 2 fills | Director | Sell 10b5-1 | 9,288 | $35.07 | $325.7K | 352,767 −2.6% of holding | |
| Lu Peng | Chief Medical Officer | Sell 10b5-1 | 14,700 | $34.00 | $499.8K | 65,631 −18.3% of holding | |
| Lu Peng 2 fills | Chief Medical Officer | Sell 10b5-1 | 15,000 | $34.60 | $519.0K | 69,031 −17.9% of holding | |
| Lesage Anne 2 fills | Chief Early Development | Sell 10b5-1 | 4,600 | $35.12 | $161.6K | 131,669 −3.4% of holding | |
| Lu Peng | Chief Medical Officer | Sell 10b5-1 | 300 | $34.00 | $10.2K | 65,631 −0.5% of holding | |
| Modig Berndt 2 fills | Chief Executive Officer | Sell 10b5-1 | 2,291 | $31.07 | $71.2K | 135,309 −1.7% of holding | |
| Nijdam Anna | Principal Accounting Officer | Sell | 2,670 | $30.87 | $82.4K | 46,275 −5.5% of holding | |
| Nijdam Anna | Principal Accounting Officer | Sell | 5,501 | $30.74 | $169.1K | 48,945 −10.1% of holding | |
| Nassif David W. | CFO / CLO | Sell | 10,000 | $30.31 | $303.1K | 120,300 −7.7% of holding | |
| Monges Viviane | Director | Sell | 9,667 | $30.29 | $292.9K | 5,500 −63.7% of holding | |
| Nijdam Anna | Principal Accounting Officer | Sell | 1,829 | $30.60 | $56.0K | 48,945 −3.6% of holding | |
| Bjork Elisabeth | Director | Sell 10b5-1 | 10,000 | $29.32 | $293.2K | 15,167 −39.7% of holding | |
| Modig Berndt | Chief Executive Officer | Sell 10b5-1 | 2,292 | $29.22 | $67.0K | 137,500 −1.6% of holding | |
| Souverijns Wim | Chief Commercial Officer | Sell 10b5-1 | 10,000 | $29.92 | $299.2K | 45,111 −18.1% of holding | |
| Glassman Robert 2 fills | Director | Sell | 10,000 | $29.82 | $298.2K | 15,167 −39.7% of holding | |
| Abele Stefan Andreas | Chief Technical Ops Officer | Sell | 8,748 | $29.82 | $260.9K | 35,194 −19.9% of holding | |
| Lu Peng 2 fills | Chief Medical Officer | Sell 10b5-1 | 14,166 | $30.17 | $427.4K | 66,226 −17.6% of holding | |
| Lesage Anne 3 fills | Chief Early Development | Sell 10b5-1 | 40,900 | $30.26 | $1.2M | 133,969 −23.4% of holding | |
| Schikan Johannes Gerardus Christiaan Petrus 2 fills | Director | Sell 10b5-1 | 29,070 | $30.32 | $881.4K | 355,837 −7.6% of holding | |
| Lu Peng | Chief Medical Officer | Sell 10b5-1 | 15,000 | $30.24 | $453.6K | 66,083 −18.5% of holding | |
| Lesage Anne 2 fills | Chief Early Development | Sell 10b5-1 | 7,400 | $30.07 | $222.5K | 153,169 −4.6% of holding | |
| Schikan Johannes Gerardus Christiaan Petrus | Director | Sell 10b5-1 | 3,830 | $30.07 | $115.2K | 384,237 −1% of holding | |
| Lu Peng | Chief Medical Officer | Sell 10b5-1 | 3,733 | $30.06 | $112.2K | 62,350 −5.6% of holding | |
| Lu Peng | Chief Medical Officer | Sell 10b5-1 | 100 | $30.03 | $3.0K | 66,083 −0.2% of holding | |
| Lesage Anne | Chief Early Development | Sell | 100 | $30.03 | $3.0K | 156,869 −0.1% of holding | |
| Lesage Anne | Chief Early Development | Sell 10b5-1 | 100 | $30.03 | $3.0K | 56,450 −0.2% of holding | |
| Schikan Johannes Gerardus Christiaan Petrus | Director | Sell 10b5-1 | 100 | $30.03 | $3.0K | 388,067 −0% of holding | |
| Lesage Anne 2 fills | Chief Early Development | Sell 10b5-1 | 7,500 | $30.05 | $225.4K | 56,450 −11.7% of holding | |
| Lu Peng | Chief Medical Officer | Sell 10b5-1 | 7,001 | $30.05 | $210.4K | 66,083 −9.6% of holding | |
| Schikan Johannes Gerardus Christiaan Petrus | Director | Sell 10b5-1 | 7,000 | $30.05 | $210.4K | 388,167 −1.8% of holding | |
| Lesage Anne | Chief Early Development | Sell | 7,000 | $30.05 | $210.4K | 156,969 −4.3% of holding | |
| Modig Berndt | Chief Executive Officer | Sell 10b5-1 | 2,292 | $28.60 | $65.6K | 139,792 −1.6% of holding | |
| Modig Berndt 2 fills | Chief Executive Officer | Sell 10b5-1 | 23,333 | $27.74 | $647.3K | 142,284 −14.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.